IL6R and neoplasm: IL-6 signaling can be targeted in a variety of ways, including the use of anti-IL-6 (siltuximab) or IL-6R (tocilizumab) monoclonal antibodies, which have both been extensively studied in different experimental tumor models as well as in clinical trials (55).